Home > Press > NCI Awards $26.3M to Establish Seven Centers
Abstract:
First year awards totaling $26.3 million will help establish seven Centers of Cancer Nanotechnology Excellence (CCNEs)
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), today announced the implementation of a major component of its $144.3 million five-year initiative for nanotechnology in cancer research. First year awards totaling $26.3 million will help establish seven Centers of Cancer Nanotechnology Excellence (CCNEs).
“We believe that nanotechnology will have a transformative effect on cancer diagnosis and treatment. In fact, its impact is already visible in the research being conducted through many of the centers we are announcing today,” said Andrew von Eschenbach, M.D., director of the National Cancer Institute. “Through the applications of nanotechnology, we will increase the rate of progress towards eliminating the suffering and death due to cancer.”
Nanotechnology, the development and engineering of devices so small that they are measured on a molecular scale, has demonstrated promising results in cancer research and treatment. NCI launched the plan to create the NCI Alliance for Nanotechnology in Cancer in September 2004, as a comprehensive, integrated initiative to develop and translate cancer-related nanotechnology research into clinical practice.
NCI’s Alliance for Nanotechnology in Cancer encompasses four major program components, including the CCNEs. CCNEs are multi-institutional hubs that will focus on integrating nanotechnology into basic and applied cancer research and provide new solutions for the diagnosis and treatment of cancer.
Each of the CCNE awardees is associated with one or more NCI-designated Cancer Centers, affiliated with schools of engineering and physical sciences, and partnered with not-for-profit organizations and/or private sector firms, with the specific intent of advancing the technologies being developed.
Today’s CCNE awardees (in alphabetical order) are:
“NCI has supported the application of nanotechnology to cancer through a variety of programs and interactions with the scientific community for more than seven years, and we’re very gratified that our activities are helping to advance a pipeline of new product opportunities,” noted NCI Deputy Director Anna Barker, Ph.D. “In what we believe will be a paradigm shift for cancer research, unprecedented numbers of multidisciplinary teams of basic and clinical researchers at world-class institutions are networking their research together to focus on the key cancer nanotech opportunities. The depth and diversity of the Centers of Nanotechnology Excellence award submissions were extraordinary. With the advent of the CCNEs, we are particularly looking forward to new nanotech-based therapeutic delivery systems that could enhance the efficacy and tolerability of cancer treatments — an advance that would greatly benefit cancer patients.”
Other components of the NCI Alliance for Nanotechnology in Cancer include the following:
For more information about the NCI Alliance on Nanotechnology in Cancer, please visit nano.cancer.gov. For more information about cancer, please visit the NCI Web site at www.cancer.gov or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
About NIH:
The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.
For more information, please click here
Contact:Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |